Pages
- About Us
- Basket
- Case Studies
- Collaborative Drug Discovery
- Consultancy
- Contribute Content
- Drug Discovery Screening Platform
- DUB focused research programmes
- Home Page
- Home Page New
- Keep Me Updated
- News and Events
- Privacy Policy
- Products
- Site Map
- The Ubiquitin System
- Ubiquitin System Research Tools
- Website Acceptable Use Policy
- Website Cookies Policy
- Website Terms of Use Policy
- Working With Us
Posts by category
- Category: News
- Ubiquigent appoints Professor Helen Walden and Professor John Davis to Scientific Advisory Board
- Ubiquigent celebrates milestone anniversary of DUBprofiler™ compound profiling platform
- Ubiquigent Extends and Expands Drug Discovery Collaboration with Bristol Myers Squibb
- Medivir licenses USP7 program to Ubiquigent
- Exploring the potential of DUBs and neglected tropical diseases
- Ubiquigent Continues Drug Discovery Collaboration with Bristol Myers Squibb
- COVID-19 Update: Ubiquigent fully operational
- DUBprofiler-Cell™ – target validation and compound-target engagement
- LEO Pharma Enters into Option Agreement with Ubiquigent for Access to Novel Compounds
- Targeted Protein Degradation
- Dorian Therapeutics Accesses Novel Compound Library from Ubiquigent
- Rapid Identification of Redox Cycling Compounds – REDOXprofiler™
- Ubiquigent awarded Innovate UK grant, closes further round of investment and strengthens management team
- Ubiquigent and Forma Therapeutics enter an exclusive R&D collaboration to develop novel DUB inhibitors
- Use of Ubiquigent’s DUBprofiler™ services in key 2017 publications
- Ubiquigent awarded Innovate UK grant
- Ubiquigent launches first novel compound library
- Horizon & Ubiquigent Enter into Collaboration Agreement
- Dundee, UK – the place to access world class ubiquitin system research expertise and capabilities
- Ubiquigent Strengthens Team to Deliver Cutting Edge Drug Discovery Services, Research Tools and Chemistry and Announces Launch of New Website
- Ubiquigent and Cyclofluidic Enter into Collaboration to Build Novel Ubiquitin System Targeted Compound Libraries
- Exclusive collaboration with UbiQ to commercialise novel reagents for Parkinson’s Disease research
- Dr Achim Werner awarded the Ubiquigent Young Scientist Prize
- Ubiquigent and University of Dundee announce collaboration to develop novel ubiquitin system targeted compound libraries
- Ubiquigent announces £0.5m funding and strengthens board of directors with key appointment
- Ubiquigent Ltd announces the appointment of Cosmo Bio USA Inc as their sole north American product distributor
- Ubiquigent Ltd announces expansion of its DUBprofiler™ service
- Harvard Medical School’s Prof. Alfred Goldberg delivers inaugural speech
- Stemgent announces formation of Ubiquigent, a new UK-listed biotechnology company based in Dundee, Scotland
- Category: Events
- CHI Drug Discovery Chemistry, San Diego 8-12th April
- European Protein Degradation Congress, 22nd-23rd May, Basel.
- Targeted Protein Degradation, 24th – 25th October, Boston
- 2018 BIO International Convention
- CHI Drug Discovery Chemistry, San Diego 5th April
- ELRIG networking event
- Enzymes in Drug Discovery Summit
- BioEurope Berlin
- 15th Annual Discovery on Target
- SCI: Targeting the Ubiquitin-Proteasome Pathway (19th May 2017)
- Ubiquigent attending Bio Europe 2016 – Cologne, Germany (7th-9th Nov)
- Targeted chemical libraries: the keys to unlock the ubiquitin system
- 6th GTC Ubiquitin research and drug discovery meeting
- Ubiquitin Signaling with NF-kappaB and MAP Kinase Signaling in Inflammation